Nuvectis Pharma (formerly known as Centry Pharma) is a biopharmaceutical company focused on precision medicines for cancer treatment. It develops NXP800, an inhibitor of the Heat Shock Factor 1 (“HSF1”) pathway, and NXP900, an oral small molecule SRC/YES1 kinase inhibitor. NXP800 is targeted for women with clear cell ovarian cancer and advanced-stage endometrioid ovarian carcinoma who have either the ARID1a mutation or ARID1a epigenetic loss.